Natural Alternatives International, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended June 30, 2015, compared with fiscal 2014. The request metadata says “2014 Q4,” but this filing reports the full fiscal year ended June 30, 2015.
Business context
NAI formulates and manufactures private-label nutritional supplements and related health products, and commercializes its CarnoSyn® beta-alanine patents and trademarks. It operates in the U.S. and Switzerland. Private-label manufacturing remained the core business; the company also discontinued its Pathway to Healing branded product line, with wind-down activities substantially complete by December 31, 2014.
Financial results and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Net sales | $79.5 million | $73.9 million |
| Gross profit / margin | $14.3 million / 18% | $12.7 million / 17% |
| Operating income / margin | $4.2 million / 5% | $2.8 million / 4% |
| Net income | $3.3 million | $2.0 million |
| Diluted earnings per share | $0.49 | $0.29 |
| Cash from operations | $2.7 million | $5.3 million |
| Capital expenditures | $1.7 million | $2.7 million |
- Sales rose 7.5% (reported as 8% rounded). Contract manufacturing sales increased 3.5% to $69.7 million; beta-alanine royalty, licensing and raw-material revenue increased 67.9% to $9.1 million; branded-product sales fell 39.8% to $0.7 million.
- Gross margin improved about 0.8 percentage points. Management attributed the improvement chiefly to a higher contribution from beta-alanine activity, including direct raw-material sales begun in the fourth quarter; contract manufacturing faced higher material costs.
- Operating cash flow fell despite higher earnings, primarily reflecting a $3.1 million cash use from receivables, including receivables associated with direct beta-alanine sales. Year-end receivables were $9.9 million versus $6.8 million, and inventory was $12.6 million versus $12.8 million.
- Cash and cash equivalents were $18.6 million at year-end, down from $19.5 million. Current assets were $43.6 million and current liabilities $9.1 million. No debt was outstanding; $5.5 million was available under credit facilities. Management said available liquidity and operating cash flows should cover working capital and capital expenditures for at least 12 months.
- Total liabilities were $10.0 million and stockholders’ equity was $43.9 million. The company repurchased $2.0 million of stock during FY2015; the board increased the total repurchase authorization to $5.0 million.
Material changes, outlook and risks
- NAI allowed its CSI beta-alanine licensing and distribution agreement to expire March 31, 2015, then began selling beta-alanine directly and licensing related rights. FY2015 beta-alanine revenue included $4.7 million in CSI royalties and $4.4 million in direct raw-material sales. Management expects licensing and related revenue to expand in FY2016, but results depend on patent protection, supply, distribution growth and third-party compliance.
- Management anticipated positive net income in FY2016, without assurance. It also expected continued raw-material and product-cost pressures from ingredient supply constraints and higher labor and transportation costs, and expected patent litigation expenses to be flat or slightly lower than FY2015’s approximately $1.6 million.
- Customer concentration is substantial: Juice Plus+ represented about 43% of private-label manufacturing sales, Mannatech 16%, and CIT 12%. The Juice Plus+ written supply agreement had expired, with production continuing through monthly purchase orders. Loss or reduced orders from major customers could materially affect results.
- NAI recorded a $417,000 impairment on obsolete manufacturing equipment and tooling. It reversed $190,000 of branded-product inventory reserves following better-than-expected sell-through during the product-line wind-down.
- Patent litigation is a significant contingency. The PTAB affirmed rejection of claims in NAI’s ’381 patent in July 2015; NAI’s rehearing request was pending. Reexamination and appeal proceedings concerning the ’422 patent also remained pending, alongside consolidated litigation. An adverse outcome could materially affect the beta-alanine business; legal costs and outcomes remain uncertain.
- Other notable exposures include raw-material availability and pricing, regulatory compliance and product liability, foreign exchange, and dependence on a limited customer base. NAI used foreign-exchange cash-flow hedges with $27.1 million notional value at year-end. The filing reports no outstanding debt and compliance with credit-facility covenants.
- After year-end, NAI signed a conditional agreement to sell its San Marcos headquarters; contingencies remained, and the filing says the final price and gain or loss could not yet be estimated.
Most important facts for investors to verify
- Whether direct beta-alanine distribution can sustain supply, collections, margins and revenue growth after the CSI agreement ended.
- Whether NAI can diversify sales and reduce dependence on its largest customers, particularly while key customer orders are purchase-order based.
- Current status and potential financial impact of the ’381 and ’422 patent proceedings, including legal spending and the strength of the remaining patent estate.
- Whether FY2016 earnings and liquidity expectations withstand receivable growth, input-cost pressures and operating cash-flow variability.
- Terms and completion status of the proposed headquarters sale, and any resulting proceeds or accounting impact.
The financial statements received an unqualified independent auditor’s opinion. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to attest to internal-control effectiveness.